AB0554 RISK OF CORONARY ARTERY DISEASE AND STROKE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING JAPANESE HEALTH INSURANCE DATABASE. (June 2019)

• Record Type: Journal Article
• Authors: Sakai, Ryoko; Honda, Suguru; Suzuki, Sho; Majima, Masako; Konda, Naoko; Takada, Hideto; Harigai, Masayoshi; Yamanaka, Hisashi
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1739
• Page End: 1740
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.4439
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Patients with systemic lupus erythematosus (SLE) have higher risk of coronary artery disease (CAD) and stroke than the general population 1-2 . Because these comorbidities influence on patients' vital prognosis and quality of life, it is essential for rheumatologists to manage them appropriately. Considering differences in life style and ethnicity, it is of great interest and needed to investigate risk of these comorbidities in Asia. However, to date, such evidence is scarce. Objectives: To estimate incidence rate (IR) and identify risk factors of CAD and stroke in patients with SLE using a Japanese health insurance database. Methods: This retrospective longitudinal population-based study was conducted using claims data provided by Medical Data Vision Co., Ltd (Tokyo, Japan). We defined individuals as SLE cases if they met all of the following: 1) had at least one ICD10 code (M321 or M329); 2) had at least one prescription of oral corticosteroids (CS), methylprednisolone (mPSL) pulse therapy, immunosuppressive drugs (IS) (azathioprine, mizoribine, tacrolimus, mycophenolate mofetil, cyclophosphamide, methotrexate), biologics (belimumab, rituximab) or hydroxychloroquine between April 2008 and July 2017; 3) were 16 years old or over. The start of observation was defined by the first month in which cases met all of the above criteria. Patients were followed until the earliest of date of first CAD event or stroke, date of loss of follow-up, or the end of follow-up (June 2018). CAD and stroke were defined as follows: for CAD, at least one ICD10 code (I20.x or I21.x or I23-24.x) and either percutaneous coronary intervention, coronary artery bypass procedure, or thrombolytic agents during hospitalization: for stroke, at least one ICD10 code (I60-62.x or I63-64.x) and either cerebrovascular procedures, thrombolytic agents, or antiplatelet drugs during hospitalization. Patients were excluded if they had a previous diagnosis of CAD or stroke and were prescribed antiplatelet drugs or anticoagulants during the first 3 months. We defined baseline characteristics using the data from the first 3 months, and calculated IR and adjusted hazard ratio (HR) of risk factors for CAD or stroke after adjusting for baseline characteristics using a Cox proportional hazard model. Results: In this study, 19, 138 cases were included. The median age was 53 years and 81.3% were female. Median observation period was 3.1 years. IR [95% CI]/1, 000 patient-years (PY) of CAD or stroke was 1.41 [1.11-1.77] and 4.10 [3.56-4.70], respectively. IR of any CAD or stroke was increased age-dependently (2.06 [1.47-2.80] for 16-39 years-old, 5.07 [4.36-5.86] for 40-69, 13.0 [10.9-15.5] for 70-). Adjusted HR [95% CI] was 1.37 [95% CI, 1.27-1.47] for age by decade, 3.34 [1.78-6.28] for CS use, 1.46 [1.16-1.84] for presence of hypertension (HT), 1.38 [1.04-1.85] for diabetes mellitus (DM), 1.73 [1.25-2.38] for chronic kidney disease (CKD), and 1.95 [1.15-3.32] for atrial fibrillation (AF). Conclusion: This is the first study investigating the risk of CAD or stroke in Japanese patients with SLE using a large health insurance database. Older age, use of CS, and presence of HT, DM, CKD, and AF were identified as significant risk factors of these comorbidities. References: [1] Am J Cardiol. 2004:198-200 [2] Arthritis Rheum 2009:1396-1402 Disclosure of Interests: Ryoko Sakai Grant/research support from: Tokyo Women's Medical University (TWMU) has received unrestricted research grants for Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases from Ayumi Pharmaceutical Co. Ltd., Bristol Meyers Squib, Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., and with which TWMU paid the salary of R.S. RS has received a research grant from Bristol-Meyers Squibb., Suguru Honda: None declared, Sho Suzuki: None declared, masako majima: None declared, naoko konda: None declared, hideto takada: None declared, masayoshi harigai Grant/research support from: Tokyo Women's Medical University (TWMU) has received unrestricted research grants for Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases from Ayumi Pharmaceutical Co. Ltd., Bristol Meyers Squib, Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., and with which TWMU paid the salary of MH. MH has also received research grants from AbbVie Japan GK, Eisai Co. Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Hisashi Yamanaka Grant/research support from: AbbVie, Eisai, Bristol-Meyers, Novartis, Behringer, Astellas, Kaken, Nippon-Shinyaku, Pfizer, UCB, Ayumi, Ono, Daiichi-Sankyo, Taisyo-Toyama, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, Torii, YLbio, Speakers bureau: Bristol-Meyers, Astellas, Pfizer, Daiichi-Sankyo, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, YLbio